CIPLA - Cipla Ltd. Share Price

Cipla's management provided a robust outlook during their Q3 FY26 earnings call. The company reported revenues exceeding Rs. 7,000 crores for the quarter, despite a noted decline in generic Revlimid sales. The management highlighted a strong performance from their One-India business, achieving a 10% year-on-year growth, bolstered by a 10% growth in their branded prescription segment. Key therapies, such as respiratory (11% growth), anti-diabetes, and cardiac (both at 13% growth), and urology (15% growth) significantly contributed to this performance.

Management is focusing on several strategic initiatives, including a partnership with Pfizer to market four well-established brands in India and an acquisition of Inzpera Health Sciences, which will enhance their pediatric pharmaceutical offerings. The launch of Afrezza, India's first inhaled rapid-acting insulin, is set to transform diabetes care in the country.

Looking forward, Cipla is optimistic about upcoming product launches in the U.S., particularly in the respiratory therapy segment, with four significant launches expected, including generic Advair. Management noted that the U.S. market share for Cipla's Albuterol MDI holds at 22%. Furthermore, they anticipated a resupply of Lanreotide in H1 FY27 following recent inspection challenges.

In terms of financial guidance, the EBITDA margin for FY26 is expected around 21%, influenced by the decline of Revlimid and temporary disruptions from Lanreotide. Management emphasized a commitment to maintaining operational efficiency and investing in R&D to support growth, directing approximately Rs. 494 crores towards R&D this quarter, equating to about 7% of revenue, marking a growth of 37.4% year-on-year.

Overall, Cipla's management aims to sustain growth through innovative products, strategic partnerships, and ongoing market penetration in both established and emerging markets.

Here are the major questions and their detailed answers from the Q&A section of Cipla's Q3 FY26 earnings call transcript:

1. Tushar Manudhane: "Is there anything related to Lanreotide dragging the gross profit lower compared to earlier quarters, outside Revlimid?"

   Ashish Adukia: "Revlimid significantly impacted our gross margin this quarter. Additionally, our R&D expenditures incurred costs for R&D materials and APIs, contributing to the lower margin. There was also a minor product mix dilution, but this was not substantial."

2. Kunal Dhamesha: "How much of the $66 million decline in US sales can be attributed to Revlimid versus Lanreotide?"

   Ashish Adukia: "The majority of the decline is linked to Revlimid. A smaller portion is due to Lanreotide. Without these products, our base performance remains subject to new product launches, which we anticipate will bolster future revenues."

3. Neha M.: "Will any of the peptide monetization come from the Pharmathen facility affected by FDA issues?"

   Ashish Adukia: "No, none of the peptide products we're anticipating for monetization are linked to the Pharmathen facility."

4. Damayanti Kerai: "What visibility do you have on the upcoming launches, especially peptides?"

   Achin Gupta: "We're confident about our respiratory asset launches. The approvals are progressing well, so we anticipate no issues due to current FDA site concerns."

5. Surya Narayan Patra: "Considering the lower outlook due to discontinued drugs, should we expect margins to fall below 20%?"

   Achin Gupta: "While the impact of Lanreotide and Revlimid is known, our pipeline is expected to offset these declines as we gain FDA approvals for future products. Thus, we see this as a short-term issue."

6. Bino Pathiparampil: "Was the 1,100 crores payment to Novartis related to the April 2023 deal?"

   Ashish Adukia: "Yes, it pertains to the acquisition of perpetual rights for Galvus, initially structured as an in-licensing deal."

7. Abdulkader Puranwala: "Post-Lanreotide, how will the US revenue guidance adjust?"

   Umang Vohra: "Due to Lanreotide's discontinuation, we will have to revise our previous guidance of US revenues nearing $1 billion by FY27 downwards."

8. Sidharth Negandhi: "Do you anticipate any short-term increases in market share due to the difficulties smaller firms face with Schedule M implementation?"

   Achin Gupta: "While smaller competitors may struggle, we don't foresee significant immediate changes to our brand or trade generic shares as our quality standards already exceed regulatory requirements."

9. Shashank Krishnakumar: "Are the respiratory assets filed from the US or India?"

   Umang Vohra: "Three out of four respiratory assets are indeed filed from our US sites. The fourth is from our Goa facility."

10. Chirag Dagli: "Could you clarify if there's a qualitative difference in margin expectations now that Revlimid is gone?"

    Ashish Adukia: "Going forward, we expect profitability from our respiratory lines to be lower than that of Revlimid but maintaining good gross margins due to in-house production."

These answers provide insights into Cipla's operational performance and strategic outlook moving forward, reflecting management's responses to key investor inquiries during the earnings call.